Wang Jing, Xue Ji-Su, Huang Si-Min
Department of Osteoporosis, People's Hospital of Baoan Shenzhen, the Second Affiliated Hospital of Shenzhen University, Shenzhen, China.
Department of Endocrinology, the People's Hospital of Baoan Shenzhen, the Second Affiliated Hospital of Shenzhen University, Shenzhen, China.
Curr Mol Pharmacol. 2023;16(3):321-330. doi: 10.2174/1874467215666220414145641.
Osteoporosis is becoming more prevalent in the ageing society, however, its treatment is still a problem for both society and individuals. Traditional Chinese Medicine (TCM) has a long history in treating osteoporosis and is receiving increasing attention. Multiple formulas of TCM showed satisfactory effects in treating osteoporosis in both animal models and clinical patients. However, because TCM usually consists of multiple plant and/or animal products, it is difficult to clarify the mechanism of TCM according to the requirements of Western medicine regarding purity, efficacy, dosage, and safety. With increasing researchers have started to investigate the TCM using modern scientific tools such as bioinformatics and network pharmaceutics in osteoporosis and the addition of TCM in the latest version of International Statistical Classification of Diseases and Related Health Problems (ICD-11 version, 2019) by WHO, TCM is showing large potential in treating osteoporosis although there is still a long way. The review aimed to summarize recent advancements of TCM treating osteoporosis.
在老龄化社会中，骨质疏松症正变得越来越普遍，然而，其治疗对社会和个人来说仍然是一个问题。中医在治疗骨质疏松症方面有着悠久的历史，并受到越来越多的关注。多种中药方剂在动物模型和临床患者中治疗骨质疏松症均显示出令人满意的效果。然而，由于中药通常由多种植物和/或动物产品组成，按照西医对纯度、疗效、剂量和安全性的要求，很难阐明其作用机制。随着越来越多的研究人员开始使用生物信息学和网络药理学等现代科学工具研究中药在骨质疏松症治疗中的应用，以及中药被世界卫生组织纳入最新版的《国际疾病分类及相关健康问题统计分类》（2019年第11版），尽管仍有很长的路要走，但中药在治疗骨质疏松症方面显示出了巨大的潜力。这篇综述旨在总结中医治疗骨质疏松症的最新进展。
